Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Panel Mulls Approval Of Sirion’s Durezol

This article was originally published in The Pink Sheet Daily

Executive Summary

Advisory committee will consider topical ophthalmic steroid for postoperative ocular inflammation and pain on May 29.

You may also be interested in...



Sirion Postoperative Ocular Inflammation Candidate Durezol Shows Efficacy In Twice-Daily Dosing In Phase III Study

Topical steroid has June 26 FDA action date.

Sirion’s Durezol Gets Priority Review, Late June Action Date

CEO Butler tells “The Pink Sheet” DAILY Durezol would improve on the current standard of care by offering twice-daily dosing for post-operative ocular inflammation.

IFRA Hosts Capitol Hill Scent Experience In Timeout From Policy Concerns

The International Fragrance Association North America took a break from its higher-stakes advocacy work Nov. 1 to give lawmakers and congressional staffers a "scent experience." Perfumers from six of the group's biggest members were on hand with "Scents of Home," joined by Monell Center researchers to educate attendees on the mechanics of scent and the important role it plays in people's lives.

Topics

UsernamePublicRestriction

Register

PS067815

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel